AVXL•benzinga•
Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years
Summary
Anavex's blarcamesine shows sustained cognitive and functional benefit in early Alzheimer's patients after four years of continuous treatment.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 7, 2025 by benzinga